Molecular defect in factor IXHilo, a hemophilia Bm variant: Arg----Gln at the carboxyterminal cleavage site of the activation peptide.
A genomic DNA library and the enzymatic DNA amplification technique were used to isolate human factor IX coding sequences of a hemophilia Bm variant, factor IXHilo. A point mutation that resulted in the substitution of a glutamine (CAG) for an arginine (CGG) at amino acid 180 was found in exon VI of the factor IX gene (G----A at nucleotide 20519). This mutation alters the carboxy terminal cleavage site for the activation peptide at Arg180-Val181. The arginine residue at the activation peptide cleavage site is conserved in mouse, canine, bovine, and human factor IX, suggesting that the arginine at amino acid 180 is important for normal cleavage. Sequencing of all of the coding regions of factor IXHilo revealed no other mutations. We have also shown that the point mutation in exon VI creates a new Dde I restriction site, which, in combination with the enzymatic DNA amplification technique, provides a quick, reliable, and sensitive method for carrier detection and antenatal diagnosis in affected kindreds. This is the first report of the molecular defect in a hemophilia Bm patient with a markedly prolonged ox brain prothrombin time.
Huang
M N
MN
Department of Medicine, University of North Carolina, Chapel Hill 27599.
Kasper
C K
CK
Roberts
H R
HR
Stafford
D W
DW
High
K A
KA
D000595:Amino Acid Sequence; D001483:Base Sequence; D003001:Cloning, Molecular; D005164:Factor IX / Q000235:genetics*; D005784:Gene Amplification; D006580:Genetic Carrier Screening; D002836:Hemophilia B / Q000175:diagnosis / Q000235:genetics*; D006801:Humans; D009154:Mutation; D012150:Polymorphism, Restriction Fragment Length; D013329:Structure-Activity Relationship
D005164:Factor IX